Provided is a high-affinity T cell receptor (TCR) that recognizes SSX2, wherein the TCR has the property of binding to a KASEKIFYV (SEQ ID NO: 29)-HLA A0201 complex, and the binding affinity of the TCR to the KASEKIFYV (SEQ ID NO: 29)-HLA A0201 complex is at least twice the binding affinity of a wild-type TCR to the KASEKIFYV (SEQ ID NO: 29)-HLA A0201 complex. Also provided is a fusion molecule of such a TCR with a therapeutic agent. Such a TCR can be used alone or in combination with a therapeutic agent to target tumor cells presenting the KASEKIFYV (SEQ ID NO: 29)-HLA A0201 complex.

The present invention relates to recombinant multi-specific proteins comprising binding agents with binding specificity for different targets, such as, e.g. CD3, CD33, CD123 and CD70. In addition, the invention relates to nucleic acids encoding such multi-specific proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e.g. acute myeloid leukaemia (AML), in a mammal, including a human.

Provided herein, in some embodiments, are AFFIMER® polypeptides that binds to the neonatal Fc receptor (FcRn) and extends the half-life of the polypeptides. Also provided herein, in some embodiments, are compositions containing the polypeptides, methods of using the polypeptides, and methods of producing the polypeptides.

The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.

The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

The present invention relates to a research tool for structural biology, in particular to enhance the determination of the three-dimensional structure of biological macromolecules. More specifically, the invention serves to improve the overall feasibility of structure determination providing higher resolution and better quality of the three-dimensional structures of proteins by complex-formation with a novel fusion polypeptide.

The invention provides methods for stimulating a universal immune receptor-mediated response in a mammal using cells engineered to express a universal immune receptor that comprises an adaptor molecule, such as a SpyCatcher or a SpyTag moiety, a transmembrane domain, and an intracellular domain for T cell activation.

The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia (e.g., myocardial ischemia), infarction (e.g., myocardial infarction), acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, inflammation (e.g., chronic inflammation), angiogenesis, preeclampsia, cancer and other LOX1-mediated diseases and conditions.